Paeds SAQs · allergy-and-immunology
Complement deficiencies — formative SAQs
Formative SAQs on recognising the three clinical fingerprints that earn a complement work-up, screening with CH50 and AP50 rather than a lone C3/C4, localising the block to a pathway, and tailoring prevention — meningococcal vaccination and antibiotic prophylaxis for terminal-pathway loss and C1-inhibitor-directed therapy for hereditary angioedema.
On this page & tools
Target exams
SAQ 1 (10)
A previously well fourteen-year-old boy is admitted with his second episode of invasive meningococcal septicaemia in two years. He recovered fully from the first episode and has been entirely well between admissions, with no other significant infections and normal growth. His maternal uncle died of meningococcal meningitis in childhood. His C3 and C4 are normal, but the total haemolytic complement (CH50) is undetectable, and the AP50 is normal. [9] [10]
a) What is the most likely category of diagnosis, and which pathway is affected? Explain why the child is "otherwise well" despite the recurrent invasive infection. (3 marks) [9]
b) Justify why a normal C3 and C4 does not exclude this diagnosis, and name the correct first-line screen. (2 marks) [1] [2]
c) Outline the further investigations needed to confirm the specific deficiency and to plan family screening. (2 marks) [5]
d) Discuss the principles of long-term management, including prevention, family implications, and prognosis. (3 marks) [9] [10]
SAQ 2 (10)
A twelve-year-old girl presents to the emergency department with acute swelling of her tongue and floor of mouth that has developed over four hours. She has had similar episodes of subcutaneous and abdominal swelling since the age of eight, each lasting two to three days. There is no urticaria and no itch. Her father has a history of recurrent facial swelling. She was given intramuscular adrenaline, oral antihistamines and corticosteroids in the emergency department with no improvement. Her C4 is low. [7] [8]
a) What is the most likely diagnosis, and which protein is deficient? State two features that distinguish this from histamine-mediated (anaphylaxis) angioedema. (3 marks) [7]
b) Explain why adrenaline, antihistamines and corticosteroids are ineffective, and name the appropriate acute therapy. (3 marks) [8]
c) Outline the investigations needed to confirm the diagnosis, distinguishing type I from type II. (2 marks) [7] [8]
d) Describe a long-term management plan, including on-demand therapy, prophylaxis, and an action plan. (2 marks) [8]
References
- [1]Walport MJ. Complement. First of two parts. N Engl J Med, 2001.PMID 11287977
- [2]Walport MJ. Complement. Second of two parts. N Engl J Med, 2001.PMID 11297706
- [3]Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol, 2009.PMID 19481265
- [4]Pekkarinen PT, Heikkilä N, Kisand K, et al. Dysregulation of adaptive immune responses in complement C3-deficient patients. Eur J Immunol, 2015.PMID 25446578
- [5]Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol, 2022.PMID 36198931
- [7]Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med, 2008.PMID 18768946
- [8]Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. World Allergy Organ J, 2022.PMID 35497649
- [9]Rauscher CK, Fajt ML, Bryk JA, et al. Clinical implications of C6 complement component deficiency. Allergy Asthma Proc, 2020.PMID 32867893
- [10]Ladhani SN, Campbell H, Lucidarme J, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). BMC Infect Dis, 2019.PMID 31200658